Satellos Bioscience, Inc. (MSLE) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$6.45

From 52W high−50.50%

Volume29374.00

Market cap$136.63M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$6.45

From 52W high

−50.50%

Volume

29374.00

Market cap

$136.63M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.1x

P/E (TTM)

—

RSI (14)

29.6

MomentumView details →

1D Return

−0.31%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.1x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

2.3x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−57.34%

ROA (TTM)

−52.23%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−23.08%

FCF YoY

−42.34%

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

−79.01%

MomentumView details →

1D Return

−0.31%

YTD Return

—

1Y Return

—

RSI (14)

29.6

vs 50D SMA

−25.05%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

11.22x

Quick Ratio

11.22x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.56

EPS Surprise

−9.73%

Beats (12Q)

0/12

Next Q EPS Est

−$0.63

Avg Surprise (4Q)

−13.84%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−34.31M

Op. CF (TTM)

−28.67M

Next earningsNov 13, 2026 →

Latest newsMore news →

Satellos Bioscience Inc. reported six-month interim data from its ongoing TRAILHEAD study of SAT-3247 for Duchenne muscular dystrophy.103d ago

The U.S. Food and Drug Administration granted Fast Track designation to Satellos Bioscience's drug candidate SAT-3247 for Duchenne muscular dystrophy.113d ago

Similar companies

Retension Pharmaceuticals Inc.RTSN LifeMD, Inc.LFMD Tycoon Group Holdings Limited03390.HK Kingworld Medicines Group Limited01110.HK High Tide Inc.HITI Vicore Pharma Holding ABVCRE Find similar companies →

Latest newsMore news →

Satellos Bioscience Inc. reported six-month interim data from its ongoing TRAILHEAD study of SAT-3247 for Duchenne muscular dystrophy.103d ago The U.S. Food and Drug Administration granted Fast Track designation to Satellos Bioscience's drug candidate SAT-3247 for Duchenne muscular dystrophy.113d ago